By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
Biktarvy3.36B48.29%
Other887M12.74%
Descovy807M11.59%
Trodelvy402M5.78%
Yescarta332M4.77%
Sofosbuvir/Velpatasvir283M4.07%
Genvoya264M3.79%
Vemlidy237M3.41%
Odefsey221M3.18%
Yeztugo166M2.39%
View all
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States20.88B70.90%
Europe5.06B17.20%
Other international3.5B11.90%